Table 2 Recommendation summary table
From: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
| Â | Level of evidence | Strength of recommendation |
|---|---|---|
Environmental hygiene prevention | II | A |
Efficacy and safety of palivizumab prevention | II | A |
Dose of 15Â mg/Kg once a month for 5Â months | II | A |
Prophylaxis in subjects with <29 weeks GA and aged ≤ 12 months at the beginning of epidemic season | II | A |
Prophylaxis in subjects with 29–35 weeks GA and aged ≤ 6 months at the beginning of epidemic season | IV | B |
Palivizumab prophylaxis in infants with bronchopulmonary dysplasia and aged ≤ 12 months at the beginning of epidemic season, and during the second year of life in children who require medical therapy | II | A |
Prophylaxis in infants with severe congenital heart disease and aged ≤ 12 months at the beginning of epidemic season | II | A |
Prophylaxis in infants with cystic fibrosis, Down syndrome, congenital diaphragmatic hernia, neuromuscular diseases, immunodeficiency, accumulation disorders, esophageal atresia, lung transplantation | V | B |